Synergistic anticancer effect of combination of AZD6244 and BYL719 targeting KRAS mutant in non-small cell lung cancer

被引：0
|
作者：
Jho, Eun Hye [1 ]
Kang, Sin I. [1 ]
Bae, Yeon-Hee [1 ]
Park, Young Mee [1 ]
Sun, Jong-Mu [2 ]
Ahn, Jin Seok [2 ]
Park, Keunchil [2 ]
Ahn, Myung-Ju [2 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4453
引用
收藏
页数：1
相关论文
共 50 条
  • [1] BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
    Bo Mi Ku
    Eun Hye Jho
    Yeon-Hee Bae
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    Investigational New Drugs, 2015, 33 : 12 - 21
  • [2] BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
    Ku, Bo Mi
    Jho, Eun Hye
    Bae, Yeon-Hee
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 12 - 21
  • [3] Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models
    Pia Morelli, M.
    Tentler, John J.
    Kulikowski, Gillian N.
    Tan, Aik-Choon
    Bradshaw-Pierce, Erica L.
    Pitts, Todd M.
    Brown, Amy M.
    Nallapareddy, Sujatha
    Arcaroli, John J.
    Serkova, Natalie J.
    Hidalgo, Manuel
    Ciardiello, Fortunato
    Gail Eckhardt, S.
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1051 - 1062
  • [4] Targeting KRAS in Non-Small Cell Lung Cancer
    Corral de la Fuente, Elena
    Olmedo Garcia, Maria Eugenia
    Gomez Rueda, Ana
    Lage, Yolanda
    Garrido, Pilar
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [5] A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC)
    Koh, R. Keng
    Califano, R.
    Dean, E.
    Kosmin, J.
    Ataman, O.
    Jackson, A.
    Blackhall, F. H.
    Faivre-Finn, C.
    LUNG CANCER, 2010, 67 : S33 - S34
  • [6] Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
    Zhang, Jun
    Park, Dongkyoo
    Shin, Dong M.
    Deng, Xingming
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2016, 48 (01) : 11 - 16
  • [7] Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
    Tomasini, Pascale
    Walia, Preet
    Labbe, Catherine
    Jao, Kevin
    Leighl, Natasha B.
    ONCOLOGIST, 2016, 21 (12): : 1450 - 1460
  • [8] Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
    Desage, Anne-Laure
    Leonce, Camille
    Swalduz, Aurelie
    Ortiz-Cuaran, Sandra
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC
    Mukherjee, Soumavo
    Suresh, Dhananjay
    Zambre, Ajit
    Yadavilli, Sairam
    Ghoshdastidar, Shreya
    Upendran, Anandhi
    Kannan, Raghuraman
    CANCERS, 2025, 17 (03)
  • [10] BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
    Yu, Yaya
    Xiao, Zhenzhen
    Lei, Chenjing
    Ma, Changju
    Ding, Lina
    Tang, Qing
    He, Yihan
    Chen, Yadong
    Chang, Xuesong
    Zhu, Yanjuan
    Zhang, Haibo
    BMC CANCER, 2023, 23 (01)
12345